


NEW ENGLAND EDITION

SEPTEMBER 2012


Quarterly Review of Seed, Series A and Series B/Later Round Financings: Second Quarter 2012

Activity Level of New England Seed Transactions




NUMBER OF DEALS

Activity Level of New England Series A Transactions




Activity Level of New England Series B/Later Round Transactions








Size of New England Q2 2012 Seed Transactions by Industry




Size of New England Q2 2012 Series A Transactions by Industry







Size of New England Q2 2012 Series B/Later Round Transactions by Industry



The Numbers

Dave Pierson

Activity Levels

During Q2 2012, the total number of New England Seed transactions increased 100% over Q1 2012 and decreased 11% from Q2 2011. The "other" sector represented 63% of the total Q2 2012 transactions and the technology sector accounted for the balance. There were no transactions in the life sciences or cleantech sectors.

Series A transactions during Q2 2012 increased 50% over Q1 2012 and decreased 9% from Q2 2011. The technology sector showed the strongest performance, accounting for 52% of the Q2 2012 total. The life sciences, cleantech and "other" sectors represented 19%, 5% and 24%, respectively, of the Q2 2012 total. In contrast, the technology, life sciences cleantech and "other" sectors represented 14%, 43%, 21% and 21%, respectively, of the Q1 2012 total and 52%, 35%, 0% and 13%, respectively, of the Q2 2011 total.

The total number of New England Series B/Later Round transactions during Q2 2012 increased 56% over Q1 2012 and 25% over Q2 2011. The technology sector showed the strongest performance, accounting for 66% of the Q2 2012 total, compared to 16%, 4% and 14% for the life sciences, cleantech and "other" sectors, respectively. In contrast, the technology, life sciences, cleantech and "other" sectors represented 50%, 31%, 3% and 16%, respectively, of the Q1 2012 total and 48%, 23%, 8% and 23%, respectively, of the Q2 2011 total.

At the national level, the total number of Seed transactions increased 68% over Q1 2012 (compared to a 100% increase in New England) and 9% over Q2 2011 (compared to an 11% decrease in New England). The total number of Series A transactions nationally increased 22% over Q1 2012 (compared to a 50% increase in New England) and 30% over Q2 2011 (compared to a 9% decrease in New England). The total number of Series B/Later Round transactions nationally increased 21% over Q1 2012 (compared to a 56% increase in New England) and was unchanged from Q2 2011





(compared to a 25% increase in New England). Nationally, the sector with the greatest percentage of the reported transactions for the quarter was "other," while in New England it was technology, in each case by a relatively large margin.

Deal Size

Of the New England Seed transactions during Q2 2012, 25% involved investments under \$500,000 and 63% involved investments of more than \$1 million.

Of the New England Series A transactions during Q2 2012, 57% involved investments under \$5 million and 5% involved investments over \$20 million.

Of the New England Series B/Later Round transactions during Q2 2012, 24% involved investments under \$5 million and 34% involved investments over \$20 million.

Implied Pre-Money Valuations

Seed Round

In the seven transactions reported in the implied valuation table for selected Q2 2012 New England Seed transactions, the implied pre-money valuations ranged from \$0.5 million to \$6.1 million. The results by industry sector were as follows:

- Life Sciences: There were no life sciences transactions.
- Cleantech: There were no cleantech transactions.
- Technology: There were three technology transactions, with implied pre-money valuations ranging from \$1.5 million to \$6.1 million.
- Other: There were four transactions in the "other" category, with implied pre-money valuations ranging from \$0.5 million to \$6.0 million.

Series A Round

In the nineteen transactions reported in the implied valuation table for selected Q2 2012 New England Series A transactions, the implied pre-money valuations ranged from \$2.6 million to \$31.9 million. The results by industry sector were as follows:

- Life Sciences: There were three life sciences transactions, with implied pre-money valuations ranging from \$3.5 million to \$31.9 million.
- Cleantech: There was one cleantech transaction, with an implied pre-money valuation of \$18.5 million.
- Technology: There were eleven technology transactions, with implied pre-money valuations ranging from \$2.6 million to \$27.3 million.
- Other: There were four transactions in the "other" category, with implied pre-money valuations ranging from \$3.1 million to \$12.2 million.

Series B/Later Round

In the forty transactions reported in the implied valuation table for selected Q2 2012 New England Series B/Later Round transactions, the implied pre-money valuations ranged from \$1.0 million to \$768.0 million. The results by industry sector were as follows:

- Life Sciences: There were five life sciences transactions, of which two were up rounds and three were down rounds. The implied pre-money valuations ranged from a low of \$7.0 million in a Series C down round to a high of \$768.0 million in Series F up round.
- Cleantech: There was one cleantech transaction, a Series B up round with an implied pre-money valuation of \$27.3 million.
- Technology: There were twenty-eight technology transactions, of which twenty-three were up rounds and five were down rounds. The implied pre-money valuations ranged from a low of \$1.0 million in a Series B down round to a high of \$273.7 million in a Series H up round.
- Other: There were six transactions in the "other" category, of which four were up rounds and two were even rounds. The implied pre-money valuations ranged from a low of \$14.2 million in a Series B up round to a high of \$185.6 million in a Series F even round.





Terms

The bar graph relating to terms for selected New England Series A transactions shows the following trends in Q2 2012 as compared to the immediately preceding quarter and the comparable prior year quarter:

- No change in the percentage of transactions with cumulative dividends as compared to the immediately preceding quarter and a decrease as compared to the comparable prior year quarter (43% in Q2 2012 versus 43% in Q1 2012 and 53% in Q2 2011);
- A decrease in the percentage of transactions with a participating liquidation preference as compared to the immediately preceding quarter and an increase as compared to the comparable prior year quarter (33% in Q2 2012 versus 50% in Q1 2012 and 29% in Q2 2011);
- A decrease in the percentage of transactions with a redemption provision (38% in Q2 2012 versus 57% in Q1 2012 and 65% in Q2 2011); and
- A decrease in the percentage of transactions with a pay to play provision (5% in Q2 2012 versus 14% in Q1 2012 and 18% in O2 2011).

The bar graph relating to terms for selected New England Series B/Later Round transactions shows the following trends in Q2 2012 as compared to the immediately preceding quarter and the comparable prior year quarter:

- An increase in the percentage of transactions with cumulative dividends (54% in Q2 2012 versus 25% in Q1 2012 and 49% in Q2 2011);
- A decrease in the percentage of transactions with a participating liquidation preference as compared to the immediately preceding quarter and an increase as compared to the comparable prior year quarter (48% in Q2 2012 versus 63% in Q1 2012 and 40% in Q2 2011);
- A decrease in the percentage of transactions with a redemption provision (58% in Q2 2012 versus 72% in Q1 2012 and 69% in Q2 2011); and
- A decrease in the percentage of transactions with a pay to play provision (18% in Q2 2012 versus 34% in Q1 2012 and 23% in Q2 2011).

Conclusion

Activity levels in Q2 2012 were up nicely across all size categories compared to Q1 2012. The technology sector had a particularly robust quarter, especially in the Series B/Later Round size category. These are positive developments and signs of an improving environment.

The quarterly national venture-backed exit information reported by Thomson Reuters and the National Venture Capital Association is a mixed bag:

- The number of venture-backed M&A transactions remained unchanged from Q1 2012 and increased 6% over Q2 2011; IT deals represented 75% of the Q2 2012 total.
- For venture-backed M&A transactions in Q2 2012 with reported values, 11% had transaction values less than the total venture investment, compared to 19% for Q1 2012, and 52% had transaction values greater than four times the total venture investment, compared to 58% for Q1 2012.
- Q2 2012 venture-backed IPO activity, measured by dollars raised, was the largest quarterly total on record, but this was driven by the \$16 billion Facebook IPO. Quarterly activity measured by number of deals was off significantly compared to the immediately preceding and comparable prior year quarters.

Perhaps most significantly, the trend toward consolidation in the venture capital industry continues unabated. Thomson Reuters and the National Venture Capital Association report that although new capital commitments increased over the immediately preceding and comparable prior year quarters, the number of funds raising money during Q2 2012 fell to the lowest quarterly level since Q3 2009. The top five funds account for almost 80% of the new capital commitments. This contraction in the number of venture funds with money to invest and concentration of capital commitments in an ever decreasing number of firms will have much to say about which industry sectors fall into and out of favor and will have a significant impact on entrepreneurs trying to obtain financing for their companies. For the time being, it seems clear that the companies that are most likely to receive funding are those that require relatively small amounts of capital to get to an exit, that have the ability to get to an exit relatively quickly and that don't face significant regulatory hurdles. Generally speaking, these factors tend to favor companies in the internet and software industries.





Selected New England Seed Round Transactions

Second Quarter 2012

Implied Pre-Money and Post-Money Valuations*

Company	Amount Raised	Percentage Implied Pre-Money Ownership of Seed Valuation		Implied Post-Money Valuation							
TECHNOLOGY											
Disruptor Beam, Inc.	\$600,000	29%	\$1,500,000	\$2,100,000							
Pact, Inc.	\$1,100,000	23%	\$3,700,000	\$4,800,000							
Soceaniq Inc.	\$1,100,000	16%	\$6,100,000	\$7,200,000							
		OTHER									
Cloze, Inc.	\$1,200,000	26%	\$3,500,000	\$4,700,000							
FX Aligned, Inc.	\$2,000,000	25%	\$6,000,000	\$8,000,000							
LeaseQ, Inc.	\$400,000	15%	\$2,100,000	\$2,500,000							
PollVaultr, Inc.	\$100,000	10%	\$500,000	\$600,000							

Selected New England Series A Round Transactions

Second Quarter 2012

Implied Pre-Money and Post-Money Valuations*

Company	Amount Raised	Percentage Ownership of Series A	Implied Pre-Money Valuation	Implied Post-Money Valuation							
LIFE SCIENCES											
JB Therapeutics, Inc.	\$1,700,000	12%	\$12,100,000	\$13,800,000							
PanGenX, Inc.	\$10,100,000	0,000 24% \$31,900,		\$42,000,000							
NovaTract Surgical, Inc.	\$4,800,000	58%	\$3,500,000	\$8,300,000							
		CLEANTECH									
Eye-R Systems, Inc.	\$11,000,000	37%	\$18,500,000	\$29,500,000							
		TECHNOLOGY									
Arctic Sand Technologies, Inc.	\$9,100,000	43%	\$12,000,000	\$21,100,000							
Ava, Inc.	\$5,000,000	27%	\$13,600,000	\$18,600,000							
Conversion Innovations, Inc.	\$1,900,000	42%	\$2,600,000	\$4,500,000							





Company	Amount Raised	Percentage Ownership of Series A	Implied Pre-Money Valuation	Implied Post-Money Valuation	
DataGravity, Inc.	\$12,000,000	35%	\$22,100,000	\$34,100,000	
Evoqu, Inc.	\$2,000,000	35%	\$3,500,000	\$5,500,000	
Image Stream Medical, Inc.	\$600,000	3%	\$20,000,000	\$20,600,000	
JamHub Corporation	\$1,200,000	19%	\$4,800,000	\$6,000,000	
Locu, Inc.	\$5,000,000	41%	\$7,100,000	\$12,000,000	
LuckyLabs, Inc.	\$3,500,000	11%	\$27,300,000	\$30,800,000	
Plastiq Inc.	\$2,300,000	35%	\$4,400,000	\$6,700,000	
Single Digits, Inc.	\$10,000,000	44%	\$12,900,000	\$22,900,000	
		OTHER			
Earth Ocean Farms, Inc.	\$5,000,000	42%	\$7,000,000	\$12,000,000	
Porter Square Ventures, Inc.	\$1,500,000	33%	\$3,100,000	\$4,600,000	
Smarterer, Inc.	\$1,800,000	13%	\$12,200,000	\$14,000,000	
The Answer Page, Inc.	\$500,000	4%	\$10,600,000	\$11,000,000	

Selected New England Series B/Later Round Transactions

Second Quarter 2012

Implied Pre-Money and Post-Money Valuations*

Company	Most Recent Series of Preferred Stock (A, B, C, etc.)	Amount Raised	Ount Raised Percentage Ownership of Most Recent Series		Implied Post-Money Valuation	Up or Down Round					
LIFE SCIENCES											
Seahorse Bioscience, Inc.	I	\$22,200,000	21%	\$84,300,000	\$106,600,000	Up					
Beacon Endoscopic Corporation	С	\$5,200,000	24%	\$16,800,000	\$22,000,000	Down					
Castlewood Surgical, Inc.	С	\$1,000,000	12%	\$7,000,000	\$8,000,000	Down					
ConforMIS, Inc.	F	\$84,000,000	10%	\$768,000,000	\$852,000,000	Up					
Grove Instruments, Inc.	В	\$6,000,000	12%	\$44,000,000	\$50,000,000	Down					
CLEANTECH											
Liquid Metal Battery Corporation	В	\$15,400,000	36%	\$27,300,000	\$42,700,000	Up					





Company	Most Recent Series of Preferred Stock (A, B, C, etc.)	Amount Raised	Percentage Ownership of Most Recent Series	Implied Pre-Money Valuation	Implied Post-Money Valuation	Up or Down Round				
TECHNOLOGY										
Bradford Networks, Inc.	F	\$3,000,000	15%	\$17,000,000	\$20,000,000	Down				
Continuity Engine, Inc.	С	\$4,300,000	41%	\$6,200,000	\$10,400,000	Up				
Copiun, Inc.	С	\$1,500,000	16%	\$8,000,000	\$9,500,000	Up				
CustomMade Ventures Corp.	В	\$4,100,000	20%	\$16,000,000	\$20,100,000	Up				
Fiksu, Inc.	С	\$10,000,000	9%	\$100,900,000	\$110,900,000	Up				
FirstBest Systems, Inc.	D	\$11,400,000	23%	\$37,300,000	\$48,700,000	Up				
Fusion Optix, Inc.	D	\$9,700,000	50%	\$9,700,000	\$19,400,000	Down				
Greenbytes, Inc.	В	\$5,000,000	11%	\$40,800,000	\$45,800,000	Up				
Gridco, Inc.	В	\$8,000,000	17%	\$37,800,000	\$45,800,000	Up				
Intronis, Inc.	В	\$2,800,000	11%	\$22,700,000	\$25,500,000	Up				
Kaminario	D	\$25,300,000	16%	\$133,000,000	\$158,300,000	Up				
Lantos Technologies, Inc.	С	\$6,600,000	22%	\$23,000,000	\$29,500,000	Up				
MineralTree, Inc.	В	\$6,300,000	33%	\$12,900,000	\$19,200,000	Up				
NuoDB, Inc.	В	\$20,200,000	46%	\$24,000,000	\$44,200,000	Up				
OnePIN, Inc.	В	\$1,300,000	21%	\$4,700,000	\$6,000,000	Up				
Paydiant, Inc.	В	\$16,000,000	25%	\$48,200,000	\$64,200,000	Up				
Plexxi Inc.	С	\$20,100,000	9%	\$212,900,000	\$233,000,000	Up				
PlumChoice, Inc.	G	\$10,000,000	10%	\$86,200,000	\$96,200,000	Down				
Rethink Robotics, Inc.	D	\$32,000,000	21%	\$119,100,000	\$151,100,000	Up				
Sand 9, Inc.	С	\$27,900,000	37%	\$48,200,000	\$76,100,000	Down				
Session M, Inc.	В	\$20,100,000	21%	\$74,500,000	\$94,600,000	Up				
Sonian Inc.	С	\$13,600,000	30%	\$31,500,000	\$45,100,000	Up				
Terascala, Inc.	В	\$16,400,000	38%	\$27,000,000	\$43,400,000	Up				
Terrafugia, Inc.	D-2	\$6,500,000	10%	\$56,000,000	\$62,500,000	Up				
Unidesk Corporation	С	\$9,000,000	15%	\$50,900,000	\$59,900,000	Up				
Veracode, Inc.	Н	\$30,000,000	10%	\$273,700,000	\$303,700,000	Up				
Vermedx, Inc.	В	\$1,300,000	57%	\$1,000,000	\$2,200,000	Down				






Company	Most Recent Series of Preferred Stock (A, B, C, etc.)	Amount Raised	Percentage Ownership of Most Recent Series	Implied Pre-Money Valuation	Implied Post-Money Valuation	Up or Down Round
Visual IQ, Inc.	С	\$10,000,000	19%	\$41,500,000	\$51,500,000	Up
			OTHER			
Care.com, Inc.	F	\$23,400,000	11%	\$185,600,000	\$209,000,000	Even
CashStar Inc.	F	\$5,000,000	6%	\$76,000,000	\$81,000,000	Up
Connectedu, Inc.	F	\$71,300,000	75%	\$23,500,000	\$94,700,000	Even
Dailybreak, Inc.	В	\$5,300,000	27%	\$14,200,000	\$19,400,000	Up
Direct Vet Marketing, Inc.	С	\$4,100,000	12%	\$30,800,000	\$34,900,000	Up
Unreal Brands, Inc.	С	\$10,000,000	7%	\$130,000,000	\$140,000,000	Up

^{*}The numbers in the three tables above are estimates. This analysis is inherently imprecise and is based on a number of general assumptions which may or may not be applicable to a given transaction. Accordingly, the data in the tables for a particular transaction may not accurately reflect the actual circumstances of the transaction. In a typical situation, however, we believe that our analysis yields an approximation of the valuation placed on the company at the time of financing, and therefore may be of interest to our readers.

We can prepare a similar analysis across any group of transactions that our clients are interested in. For example, we could prepare an analysis for a group of competitive companies so you can see what the implied valuations of your competitors are. If you would like additional information on this service, please contact your lawyer at Foley Hoag or one of our Emerging Enterprise Center lawyers listed at the end of this publication.


Terms of Selected New England Seed Rounds 2012








Terms of Selected New England Series A Rounds 2011-2012



Terms of Selected New England Series B/Later Rounds 2011-2012







The three charts above summarize publicly available information about various terms included in the Certificates of Incorporation for Seed, Series A and Series B / Later Round financings for companies headquartered in New England. We have selected terms to report on that we believe will be of particular interest to entrepreneurs. A definition of each of these terms may be found on our website, www.emergingenterprisecenter.com. Information included in the tables above is based on information made publicly available by participants in the relevant transactions and is not comprehensive.

We can prepare a similar analysis across any group of transactions that our clients are interested in. For example we could prepare an analysis by industry so you can see what terms are prevalent in your industry. If you would like additional information on this service, please contact your lawyer at Foley Hoag or one of our Emerging Enterprise Center lawyers listed at the end of this publication.

The National Activity Level Summary

National Seed Transactions by Industry*

		20	11			2012				
Industry	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Quarter ended June 30, 2011	Quarter ended June 30, 2012
Life Sciences										
Biopharma	5	4	6	4	1	1			4	1
Medical Device	2	3	4	4	6	2			3	2
Cleantech	0	0	0	0	2	1			0	1
Technology	30	34	18	23	18	28			34	28
Other	38	27	39	39	17	42			27	42
Total	75	68	67	70	44	74			68	74

^{*} Source: Dow Jones VentureSource

National Series A Transactions by Industry*

		20	11			2012				
Industry	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Quarter ended June 30, 2011	Quarter ended June 30, 2012
Life Sciences										
Biopharma	13	26	24	20	9	12			26	12
Medical Device	11	21	13	14	15	17			21	17
Cleantech	9	2	6	6	7	4			2	4
Technology	53	61	69	76	82	76			61	76
Other	85	98	123	124	110	162			98	162
Total	171	208	235	240	223	271			208	271

^{*} Source: Dow Jones VentureSource





National Series B/ Later Round Transactions by Industry*

		20	11			2012				
Industry	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Quarter ended June 30, 2011	Quarter ended June 30, 2012
Life Sciences										
Biopharma	36	43	40	55	43	35			43	35
Medical Device	45	53	49	43	52	45			53	45
Cleantech	21	25	30	21	15	11			25	11
Technology	93	108	131	120	115	147			108	147
Other	188	219	169	181	143	209			219	209
Total	383	448	419	420	368	447			448	447

^{*} Source: Dow Jones VentureSource





If you have any questions about this publication or about the Emerging Enterprise Center at Foley Hoag and how we can help your entrepreneurial venture, please feel free to contact any of the following key members of the Foley Hoag legal team resident at the EEC:



Gil Arie Partner garie@foleyhoag.com 617 832 1781



Dave Broadwin
Partner
dbroadwin@foleyhoag.com
781 895 5905



Hemmie Chang Partner hchang@foleyhoag.com 617 832 1175



Matt Eckert
Associate
meckert@foleyhoag.com
617 832 3057



Mark Haddad Partner mhaddad@foleyhoag.com 617 832 1724



Kanasha Herbert
Associate
kherbert@foleyhoag.com
617 832 1173



Pia Owens Associate powens@foleyhoag.com 617 832 1739



Dave Pierson
Partner
dpierson@foleyhoag.com
617 832 1146



Paul Sweeney
Partner
psweeney@foleyhoag.com
617 832 1296



Prithvi Tanwar Associate ptanwar@foleyhoag.com 617 832 3045



Amanda Vendig Associate avendig@foleyhoag.com 781 895 5960



Bob Warren Partner rwarren@foleyhoag.com 617 832 3075

Lawyers driven to help you succeed

The Emerging Enterprise Center at Foley Hoag (the "EEC") is the centerpiece of Foley Hoag's long-standing and market-leading legal practice representing early-stage technology companies and their founders and investors. At the EEC, we work closely with start-up and emerging companies in a variety of technology industries throughout their entire lifecycle, from inception through financing, growth and maturity. In addition, the EEC team and the events we host provide opportunities for entrepreneurs and investors to learn and to connect with potential partners. We are proud to be a sponsor of and an active participant in the vibrant New England entrepreneurial community that has brought so many successful companies and innovative technologies to the world. Visit the EEC at www.emergingenterprisecenter.com.

Foley Hoag is a dynamic law firm that represents public and private clients in a wide range of disputes and transactions worldwide. We have expertise in industries such as life sciences and healthcare, technology, energy and renewables, investment management, and professional services. We also offer our clients market-leading international litigation and arbitration and corporate social responsibility services. From our offices in Boston, Washington, D.C. and Paris, and our Emerging Enterprise Center in Waltham, Massachusetts, we provide strategic legal advice that is tailored to each of our clients' unique goals. Foley Hoag combines powerful regional, national and international practices that share a common emphasis on client service. We are focused on what we do best: helping our clients succeed through the delivery of exceptional legal service. For more information, visit www.foleyhoag.com.

This publication is for information purposes only and should not be construed as legal advice or legal opinion on any specific facts or circumstances. You are urged to consult your own lawyer concerning your own situation and any specific legal questions you may have. United States Treasury Regulations require us to disclose the following: Any tax advice included in this publication and its attachments is not intended or written to be used, and it cannot be used by the taxpayer, for the purpose of avoiding penalties that may be imposed on the taxpayer.

This communication is intended for general information purposes and as a service to clients and friends of Foley Hoag LLP. This communication should not be construed as legal advice or a legal opinion on any specific facts or circumstances, and does not create an attorney-client relationship.

Attorney advertising. Prior results do not guarantee a similar outcome. © 2012 Foley Hoag LLP. All rights reserved.